Regeneron Pharmaceuticals (REGN)
$281.62
2.56 (0.90%)
REGN Stock Quote Delayed 15 Minutes
Previous Close
$281.62
Market Cap
29.84B
PE Ratio
22.82
EPS
12.34
Volume (Avg. Vol.)
617,100
Day's Range
279.47 - 287.00
52-Week Range
271.57 - 442.00
Dividend & Yield
N/A (N/A)
REGN Stock Predictions, Articles, and Regeneron Pharmaceuticals News
3 Biotech Stocks That Show The Good, The Bad and the Ugly Side of This Sector
When rumors start buzzing that the government may be about to intervene, then biotech stocks often get slammed...some fairly, and some not (as we’ll see).
Nasdaq Today: Biotech Wrecked; Buy Microsoft?
Investors saw new highs in the Nasdaq today, but the index finished slightly lower on the day. Here's what we're watching now.
Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?
Trump says that Facebook and Alphabet should be sued, while Micron surged on earnings. Semiconductors got a big boost in the Nasdaq today as well.
Regeneron Pharmaceuticals Earnings: REGN Stock Drops on Q1 Miss
Regeneron Pharmaceuticals earnings for the first quarter of 2019 have REGN stock falling on Tuesday due to poor results for the period.
This Is Why You Shouldn’t Count Regeneron Stock Out
When drug companies fall out of favor, as now, I look first to companies with a method for drug discovery like Regeneron stock.
Market Leadership’s Odd Couple: Wingstop and Regeneron
It might seem like an odd pairing, but WING and REGN stock have similar leadership qualities off and on the price chart.
Value Investors Should Buy into the Teva Stock Dip
Teva stock is now at yearly lows, a victim of negative macro news, falling stock markets, and year-end tax-loss selling.
Biogen Stock Rebounds After Impressive Q3 Earnings
Biogen stock reaffirmed its dominance in MS and the neurosciences market. At a low P/E mutliple, investors should look at BIIB again.
Navellier Ratings
Powered by Portfolio GraderTotal Grade
D
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!
